[Featured Stock] Wooridul Hu Brain Highlights Stake in Partner BBB Amid Imminent Launch of Celltrion COVID-19 Diagnostic Kit
[Asia Economy Reporter Minwoo Lee] Wooridle Brain's stock price is on the rise. Investors seem to have flocked to the news that 'VIVIVI,' a diagnostic kit specialist company holding about 10% of the shares, is about to launch a new coronavirus disease (COVID-19) diagnostic kit developed together with Celltrion.
As of 9:50 AM on the 24th, Wooridle Brain's stock price recorded 3,730 won, rising to the maximum daily price increase limit (29.97%) compared to the previous day. The announcement that Celltrion plans to launch the COVID-19 antigen rapid diagnostic (POCT) kit jointly developed with VIVIVI next month appears to have acted as a positive factor. This diagnostic kit is expected to be rapidly distributed as it can provide results within 20 minutes. The two companies plan to complete certification for the product within this month and begin overseas supply.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
Previously, Wooridle Brain acquired a 10.01% stake in VIVIVI last month for about 7.5 billion won.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
